Clinical Laserthermia Systems revises its strategy to increase the possibility of achieving the goal of reaching a positive cash flow in 2026. The new strategy prioritizes the neurosurgery business area, enabling cost savings of approximately SEK 65 million.
- The background to the announced changes to the business is the strength of the ClearPoint Prism product offering, a strength that has become increasingly clear in the spring of 2024 through the initial market launch in the US, CLS writes.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/05/cls-revises-strategy-increases-focus-on-neurosurgery/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/cls/r/biostock-cls-revises-strategy---increases-focus-on-neurosurgery,c3987454

(c) 2024 Cision. All rights reserved., source Press Releases - English